Archive

December 2025

Browsing

The Department of Justice said Wednesday it may have more than a million more documents related to the late Jeffrey Epstein that it needs to review and that the process could take weeks to complete.

The DOJ said two of its components, the FBI and the U.S. Attorney’s Office for the Southern District of New York, had just handed over the missing tranche of files, days after the Epstein Files Transparency Act deadline had passed.

‘We have lawyers working around the clock to review and make the legally required redactions to protect victims, and we will release the documents as soon as possible,’ the DOJ wrote in a statement on social media.

The ‘mass volume of material’ could ‘take a few more weeks’ to review, the DOJ said.

‘The Department will continue to fully comply with federal law and President Trump’s direction to release the files,’ the department wrote.

The DOJ has been sharing on a public website since Friday tens of thousands of pages of files related to Epstein’s and Ghislaine Maxwell’s sex-trafficking cases as part of its obligation under the transparency bill. 

President Donald Trump signed the bill into law Nov. 19, giving the DOJ 30 days to review and release all unclassified material related to the cases.

The file rollout has stirred controversy as critics have blasted the DOJ for what they say are excessive redactions and the law’s lapsed deadline Friday. Initially, the DOJ said it would miss the deadline by a couple of weeks, but Wednesday’s announcement signals that might extend further into the new year than the administration had anticipated.

Deputy Attorney General Todd Blanche said on ‘Meet the Press’ Sunday there was ‘well-settled law’ that supported the DOJ missing the bill’s deadline because of a need to meet other legal requirements, like redacting victim-identifying information.

The transparency bill required the DOJ to withhold information about victims and material that could jeopardize open investigations or litigation. Officials could also leave out information ‘in the interest of national defense or foreign policy,’ the bill said. 

The bill also explicitly directed the DOJ to keep visible any details that could be damaging to high-profile and politically connected people.

This post appeared first on FOX NEWS

Nasry Asfura has won the 2025 Honduras presidential election, delivering victory for the right-of-center National Party of Honduras (PNH) and shifting the political landscape of Central America. 

The 40.3% to 39.5% result in favor of Asfura over Liberal Party candidate Salvador Nasralla arrived after the vote-counting process had been delayed for days by technical glitches and claims by other candidates of vote-rigging. Rixi Moncada, the candidate of the ruling LIBRE party, came in a distant third.

The results of the race were so tight and the ballot processing system was so chaotic, that about 15% of the tally sheets, which accounted for hundreds of thousands of ballots, had to be counted by hand to determine the winner.

Two electoral council members and one deputy approved the results despite disputes over the razor-thin difference in the vote. A third council member, Marlon Ocha, was not in a video declaring the winner.

‘Honduras: I am ready to govern. I will not let you down,’ Asfura said on X after the results were confirmed.

The head of the Honduran Congress, though, rejected the results and described them as an ‘electoral coup.’

‘This is completely outside the law,’ Congress President Luis Redondo of the LIBRE party said on X. ‘It has no value.’

Secretary of State Marco Rubio congratulated Asfura on X, saying the U.S. ‘looks forward to working with his administration to advance prosperity and security in our hemisphere.’

Initially, preliminary results on Monday showed Asfura, 67, had won 41% of the ballot, inching him ahead of Nasralla, 72, who had around 39%.

On Tuesday, the website set up to share vote tallies with the public experienced technical problems and crashed, according to The Associated Press.

With the candidates only having 515 votes between them, a virtual tie and site crash saw President Trump share a post on Truth Social.

‘Looks like Honduras is trying to change the results of their Presidential Election,’ he wrote. ‘If they do, there will be hell to pay!’

By Thursday, Asfura had 40.05%, about 8,000 votes ahead of Nasralla, who had 39.75%, according to Reuters, with the latter then calling for an investigation.

‘I publicly denounce that today, at 3:24 a.m., the screen went dark and an algorithm, similar to the one used in 2013, changed the data,’ Nasralla wrote on social media, adding 1,081,000 votes for his party were transferred to Asfura, while 1,073,000 votes for Asfura’s National Party were attributed to him.

Asfura, nicknamed ‘Tito,’ is a former mayor of Tegucigalpa and had entered the race with a reputation for leadership and focus on infrastructure, public order and efficiency.

His win ended a polarized campaign season, with one of the defining moments of the contest being Asfura’s endorsement by Trump.

‘If he [Asfura] doesn’t win, the United States will not be throwing good money after bad,’ Trump wrote on his Truth Social platform Nov. 28.

Before the start of voting Nov. 29, Trump also said he would pardon former President Juan Orlando Hernandez, who once led the same party as Asfura. Hernandez is serving a 45-year sentence for helping drug traffickers.

In the end, the election saw the defeat of centrist former vice president of Honduras, Nasralla and left-wing Moncada, 60, who served under President Xiomara Castro. 

Moncada, a prominent lawyer, financier and former minister of national defense, focused on institutional reform and social equity.

Nasralla, a high-profile television personality turned politician, mobilized a base but fell short of converting his popularity into a winning coalition.  

He was focusing on cleaning up Honduran corruption. The Honduran presidential race was also impacted by accusations of fraud.

In addition to electing a new president, Hondurans voted for a new Congress and hundreds of local positions.

Reuters contributed to this report.

This post appeared first on FOX NEWS

A group of 19 Democrat-led states and Washington, D.C., filed a lawsuit against the Trump administration over a declaration that aims to restrict gender transition treatment for minors.

The lawsuit against the U.S. Department of Health and Human Services; its secretary, Robert F. Kennedy Jr.; and its inspector general comes after the declaration issued last week described treatments such as puberty blockers, hormone therapy and gender surgeries as unsafe and ineffective for children experiencing gender dysphoria.

The declaration also warned doctors they could be excluded from federal health programs, including Medicare and Medicaid, if they provide these treatments to minors.

The move seeks to build on President Donald Trump’s executive order in January calling on HHS to protect children from ‘chemical and surgical mutilation.’

‘We are taking six decisive actions guided by gold standard science and the week one executive order from President Trump to protect children from chemical and surgical mutilation,’ Kennedy said during a press conference last week.

HHS has also proposed new rules designed to further block gender transition treatment for minors, although the lawsuit does not address the rules, which have yet to be finalized.

The states’ lawsuit, filed Tuesday in Eugene, Oregon, argues that the declaration is inaccurate and unlawful and urges the court to prevent it from being enforced.

‘Secretary Kennedy cannot unilaterally change medical standards by posting a document online, and no one should lose access to medically necessary health care because their federal government tried to interfere in decisions that belong in doctors’ offices,’ New York Attorney General Letitia James, who led the lawsuit, said in a statement.

The lawsuit claims the declaration attempts to pressure providers into ending gender transition treatment for young people and circumvent legal requirements for policy changes. The complaint said federal law requires the public be given notice and an opportunity to comment before substantively amending health policy and that neither of these were done before the declaration was released.

The declaration based its conclusions on a peer-reviewed report that the department conducted earlier this year that called for more reliance on behavioral therapy rather than broad gender transition treatment for minors with gender dysphoria.

The report raised questions about standards for the treatment of transgender children issued by the World Professional Association for Transgender Health and brought concerns that youths may be too young to give consent to life-changing treatments that could result in future infertility.

Major medical groups and physicians who treat transgender children have criticized the report as inaccurate.

HHS also announced last week two proposed federal rules — one to cut off federal Medicaid and Medicare funding from hospitals that offer gender transition treatment to children and another to block federal Medicaid money from being used for these procedures.

The proposals have not yet been made final and are not legally binding because they must go through a lengthy rulemaking process and public comment before they can be enforced.

Several major medical providers have already pulled back on gender transition treatment for youths since Trump returned to office, even those in Democrat-led states where the procedures are legal under state law.

Medicaid programs in just under half of states currently cover gender transition treatment. At least 27 states have adopted laws restricting or banning the treatment, and the Supreme Court’s decision this year upholding Tennessee’s ban likely means other state laws will remain in place.

Democrat attorneys general from California, Colorado, Connecticut, Delaware, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New Mexico, Oregon, Rhode Island, Vermont, Wisconsin, Washington state and Washington, D.C., as well as Pennsylvania’s Democrat governor, joined James in the lawsuit.

The Associated Press contributed to this report.

This post appeared first on FOX NEWS

A Christmas Eve jazz concert at the Kennedy Center was canceled just days after the White House announced that President Donald Trump’s name would be added to the iconic performing arts institution in Washington, D.C.

The show’s host, musician Chuck Redd, who has led the holiday ‘Jazz Jams’ at the Kennedy Center since 2006, said he called off his performance after Trump’s name was added to the facility.

‘When I saw the name change on the Kennedy Center website and then hours later on the building, I chose to cancel our concert,’ Redd told the Associated Press.

Fox News Digital has reached out to the Kennedy Center for comment. The Kennedy Center’s website lists the show as canceled.

The Kennedy Center’s board voted unanimously on Dec. 18 to rename the institution the ‘Trump-Kennedy Center,’ prompting swift backlash from members of the Kennedy family who said the decision undermined the legacy of President John F. Kennedy.

Maria Shriver, Kennedy’s niece, criticized the decision, calling it ‘beyond comprehension.’

Last week, workers added Trump’s name to the outside of the center, and the website’s header was changed to ‘The Trump Kennedy Center.’

Another Kennedy niece, Kerry Kennedy, vowed to remove Trump’s name from the building after he leaves office.

President Lyndon Johnson signed a bill in 1964 that designated the center as a living memorial to Kennedy following his assassination in 1963. The law prohibits the board of trustees from making the center into a memorial to anyone else or from putting another person’s name on the building’s exterior, the AP reported.

Trump was elected chairman of the Kennedy Center board in February, after removing 18 trustees appointed by former President Joe Biden.

Since Trump returned to office on Jan. 20, several artists have canceled performances at the Kennedy Center, including Lin-Manuel Miranda, who called off a production of ‘Hamilton.’

Redd has toured worldwide and performed with numerous musicians, including Dizzy Gillespie, according to his website bio.

Fox News Digital has reached out to Redd for comment.

The Associated Press contributed to this report.

This post appeared first on FOX NEWS

North Korea showed off its apparent progress in the development of a nuclear-powered submarine. State media released photos of North Korean dictator Kim Jong Un and his daughter, a potential heir, as they inspected what appears to be a largely completed hull.

The Korean Central News Agency (KCNA), North Korea’s official state media, said Kim and his daughter visited the shipyard to examine the construction of what it describes as an 8,700-ton-class nuclear-propelled submarine, The Associated Press reported. Pyongyang has signaled that it plans to arm the submarine with nuclear weapons, the AP noted. Kim has said the development of the submarine is a crucial step toward the modernization and nuclear armament of his country’s navy.

The Christmas Day release of the photos marks the first time North Korean state media has shown an update on the nuclear-powered submarine since March. Earlier images mostly showed the lower sections of the vessel, the AP noted. The KCNA did not say when the photos released on Thursday were taken.

Moon Keun-sik, a submarine expert at Seoul’s Hanyang University, told the AP that the photos of a largely completed hull indicate that many of the core components are already in place, as submarines are typically built from the inside out. However, it was not immediately clear exactly how much progress Pyongyang had made.

‘Showing the entire vessel now seems to indicate that most of the equipment has already been installed and it is just about ready to be launched into the water,’ Moon, who also served as a submarine officer in the South Korean navy, told the AP. Moon added that North Korea’s submarine could be ready for testing at sea within months.

While at the shipyard, Kim condemned South Korea’s efforts to develop its own nuclear-powered submarine as an ‘offensive act,’ despite the fact that President Donald Trump has backed Seoul’s push toward the technology. Kim said South Korea’s efforts violate North Korea’s security and maritime sovereignty, according to the AP.

In October, during his tour of Asia aimed at securing investments, Trump said that the U.S. would share technology with South Korea that would allow it to build a nuclear-powered submarine. The president posted on Truth Social that the vessel would be built in Philadelphia.

‘South Korea will be building its nuclear-powered submarine in the Philadelphia shipyards, right here in the good ol’ U.S.A. Shipbuilding in our country will soon be making a BIG COMEBACK,’ the president wrote.

The White House underscored the point when it released a fact sheet in November which directly referenced Washington and Seoul’s efforts to ‘further our maritime and nuclear partnership.’

The Associated Press contributed to this report.

This post appeared first on FOX NEWS

The biotech sector is entering 2026 with a positive outlook, characterized by reasonable valuations, robust oncology momentum and supportive policy tailwinds. This combination is setting the stage for a continued recovery, driven in part by the integration of artificial intelligence (AI).

However, this sectoral resurgence must navigate a tug-of-war between supportive stimulus and structural risks, which have the potential to challenge the pace of recovery.

Biotech sector rebounding after US uncertainty

According to Song, biotech has rebounded since its lows in April of this year.

Company valuations are trading at a 15 percent discount to broader markets on forward price-to-earnings, with secular demand intact for oncology, obesity and chronic diseases. In Song’s view, the biotech industry’s rebound stems from reduced uncertainty under the administration of US President Donald Trump.

Song added that valuations across healthcare are reasonable, noting rotational flows from cooling AI hype.

“I can’t deny that there have been some rotational effects that not just biotech has benefited (from), but healthcare in general,’ he commented. “While AI is an important driver in healthcare, to our view, it certainly is not priced in to the largest extent in many pockets of healthcare.”

Key biotech sector catalysts in 2026

Song sees healthcare’s recovery extending into 2026, with oncology remaining the primary growth engine.

He characterized the current sector resurgence as a durable structural shift being fueled by key developments that present tangible investment opportunities, including anticipated positive clinical trial outcomes, such as those for Revolution Medicines’ (NASDAQ:RVMD) pancreatic cancer drug.

“They have a lead drug that blocks an important pathway called RAS … and they could have a potential breakthrough in pancreatic cancer. They’re running a Phase III trial to demonstrate a potential survival benefit. There could be meaningful progress there,” Song noted. A data readout is expected next year.

Outside oncology, Song flagged high-profile biotech catalysts that could broaden the sector’s 2026 rally.

“Non-peptide oral GLP-1s … are clearly going to be an important data set readout and launch that could occur next year,” he explained, citing Eli Lilly’s (NYSE:LLY) orforglipron, a daily pill that hit Phase III success for type 2 diabetes and obesity in 2025. Approval is expected in 2026, and he believes it could be a potential game changer in obesity and chronic disease treatments, an area dominated by biotech innovators.

Song also sees validation ahead for platform technologies.

A dual-track recovery for biotech

While macro analysts see a broad cyclical recovery in 2026, Song predicts that the market will be defined by a dual-track recovery: a diagnostics-led initial public offering (IPO) surge, and a biopharma M&A environment focused on companies with the clinical validation required to alter the current standard of care.

Renaissance Capital predicts a faster pace for biotech IPOs, with a strong pipeline of companies such as Aktis Oncology, a radiopharma diagnostics firm targeting solid tumors, ready to list for US$100 million.

Additionally, AlphaSense forecasts steady M&A flow as companies rebuild their pipelines in the new year, a trend that Song sees as a structural necessity rather than a simple trend. “It’s an important pillar where Big Pharma needs to replenish their pipelines, and they can’t all do it internally,” he explained.

Consequently, he believes the primary “hunting ground” for these deals is mid-cap territory, where acquiring one or two proven drugs can effectively move the needle for a large pharmaceutical giant.

AI in the biotech sector

Song maintained that AI has not reached full valuation in the sector, and its role is expected to grow, with significant future productivity gains predicted in biopharma, drug discovery, clinical development and healthcare delivery.

“We’ve done some preliminary work that that that suggests there could be … productivity gains in areas like biopharmaceuticals and drug discovery and clinical development,” Song explained, adding that these are long-term projections. He sees a more immediate economic impact in how care is managed.

“Since healthcare is a large part of the US and global economy, and growing quickly in terms of healthcare costs, there are also opportunities for efficiency gains, which could lead to margin and consumer gains,” he noted. This revolution in delivery is already a key focus for his firm’s Tema Oncology ETF (NASDAQ:CANC).

However, life science market analyst Anastasia Bystritskaya warned that valuation and productivity are not synonymous, as high-performing models do not automatically become revenue-producing products. For investors, the real inflection point is operational integration rather than operating as a standalone prototype.

Drive for efficiency is expected to take a practical form in 2026 through what Sergey Jakimov, managing partner at longevity and biotech venture capital firm LongeVC, described as the “doctor in your hand.”

This AI companion manages routine, low-complexity tasks between clinic visits.

LongeVC anticipates that this shift to a regulated digital workflow will allow AI to identify meaningful clinical signals continuously without overburdening primary care teams.

This democratization of discovery creates a new competitive landscape for the hunting ground Song described; if AI-enabled teams can dissect complex pathways without a billion-dollar balance sheet, the traditional R&D model of Big Pharma faces a permanent disruption. In this new era, the innovation gap could be filled by agile players who use technology to act with the scale of a giant, but the speed of a startup.

Investor takeaway

Despite sector momentum, headwinds remain, particularly regarding the stability of clinical research funding.

A November report in JAMA Internal Medicine reveals that 383 clinical trials recently had their grants terminated, disrupting progress for over 74,000 participants. Dr. Gary K. Zammit, founder of Clinilabs, warned these reductions in National Institutes of Health funding risk slowing future commercial development of innovative therapies.

Macroeconomic headwinds, including rising tariffs and early labor market weakness, also present a material challenge.

Ultimately, the 2026 biotech outlook balances promising catalysts with the need for strategic capital deployment and a focus on clinically validated platform technologies, ensuring a durable expansion for the sector.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

The holiday season brings more than festive cheer, as for investors, it may signal the start of the so-called Santa Claus rally.

The Santa Claus rally is a period between the final trading days of December and the first days of January when stocks tend to climb. While this seasonal uptick isn’t guaranteed, historical data shows that markets rise more often than not during this window, driven by investor optimism, low trading volumes and year-end portfolio adjustments.

Historically, the last five trading days of December and the first two of January have been a period of above-average stock gains, offering a short, sharp rally for markets heading into the new year.

According to the Stock Trader’s Almanac, the Santa Claus rally has delivered an average gain of 1.3 percent for the S&P 500 (INDEXSP:.INX) since 1950. The phenomenon was first documented in 1972 by Yale Hirsch, founder of the Almanac, and continues to shape investor expectations today.

As for whether 2025 will deliver a Santa Claus rally to close out the year, after a choppy first half for December, markets have shown signs that a late-year recovery is possible.

When does the Santa Claus rally start?

The Santa Claus rally typically occurs over the final five trading days of December and the first two trading days of January. For 2025, the rally window begins on Wednesday, December 24, and runs through Monday, January 5, if historical patterns hold.

This narrow window often yields modest, yet consistent, returns for investors who time the market correctly.

While the rally’s timeframe is traditionally short, its effects can ripple through the market into early January. Essentially, a strong performance during this period can set the tone for January.

However, the exact timing of the Santa Claus rally can vary. Some analysts suggest that the rally has started earlier in recent years as investors attempt to front run the effect by increasing their positions in mid-December. This shift may blur the lines between the Santa Claus rally and broader December market upswings.

Will 2025 deliver a Santa Claus Rally?

This year, the S&P 500 fell during the middle of the month following a cooler-than-expected, albeit controversial, inflation report, which raised hopes for additional interest-rate cuts next year.

Despite this downturn, analysts note that a weak start to December has often failed to derail Santa’s run. Since 1950, the S&P 500 finished the Santa Claus rally period higher in 77 percent of years, even after early-month declines. By the end of the week, the index had already regained some ground, and it continued higher in the days leading up to Christmas.

“Barring any major shocks, it will be hard to fight the overwhelmingly positive seasonal period we are entering and the cleaner positioning set-up,” Goldman Sachs’ (NYSE:GS) trading desk team wrote in a note to clients, as reported by Bloomberg. ‘While we don’t necessarily see a dramatic rally, we do think there is room to go up from here into year end.”

Jeffrey Hirsch, editor-in-chief of the Stock Trader’s Almanac and Yale Hirsch’s son, also weighed in on the markets.

“It looks like (the Santa Claus rally) is set up and we can make another high by the end of the year,” he told MarketWatch. Hirsch cited cooler inflation readings and slower job growth in November, which may give the Federal Reserve room to cut interest rates in 2026.

It remains to be seen whether these predictions will come true, or if the market will be weighed down by factors including recent volatility in technology and artificial-intelligence-linked stocks.

Is the Santa Claus rally reliable?

Despite skepticism in some quarters, historical data supports the existence of the Santa Claus rally, and it is well documented.

Historically, the Santa Claus rally has been a relatively consistent period of gains. That said, historical patterns do not guarantee results, and not every year delivers the expected results. The S&P 500 lost about half a percentage point during the Santa rally period in 2024, and consecutive losses are rare but possible.

Columnist Mark Hulbert has expressed skepticism about the event in the past, noting that there is no definitive evidence that the market consistently outperforms during this period.

“An analysis of the past century reveals that the stock market in the weeks prior to Christmas is no more likely to rally than at other times of the year. (I suggest investors) ignore any arguments based on an alleged Santa Claus Rally,” Hulbert warned in an opinion piece posted on MarketWatch in 2018.

In 2019, for example, the market experienced volatility in December, defying the usual pattern.

In a December 2025 interview with CNBC, Jeffrey Hirsch cautioned that failure to rally is not an immediate bear-market signal, but rather “a flag to start looking at the other data — whether it’s seasonal indicators or other fundamental or technical measures.”

Despite the varying takes, many investors view the rally as a psychological phenomenon — one that influences market sentiment even if the returns are marginal.

Strategies for the Santa Claus rally

Now that the Santa Claus rally seems to be underway, investors interested in joining in have a variety of options, including domestic markets, international diversification or targeted sector plays such as mega-cap tech stocks.

As always, consulting with a financial advisor and conducting thorough research remains essential. While the Santa Claus rally offers potential rewards, market conditions can shift quickly, making flexibility and prudence key to success.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Craig Hemke, publisher of TFMetalsReport.com, shares his thoughts on the gold and silver markets heading into 2026, outlining why he remains bullish.

‘Just keep adding some — it’s your protection against the madness. It’ll get you through the storm,’ he said. ‘It preserves your net worth from the destruction of these bankers and politicians.’

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Altius Minerals (TSX:ALS,OTCQX:ATUSF) is making a bet on a lithium market recovery, agreeing to acquire Lithium Royalty (TSX:LIRC) in a C$520 million deal that will expand its exposure to battery metals.

Under a definitive agreement announced by the two companies on Monday (December 22), Altius plans to purchase all of the issued common and convertible common shares of Lithium Royalty for C$9.50 each.

The amount will be paid as either C$9.50 in cash or 0.24 of a common Altius share, according to shareholders’ election.

For Altius, the acquisition will allow it to bring a portfolio of 37 lithium royalties into its fold. None of them involve streams, and they span projects from production through early exploration.

Four of the royalties are tied to producing assets, three of which were commissioned in 2025 and are currently ramping up or expanding. Another 12 projects are in advanced stages with completed economic studies, while three to five additional assets are targeting startup between 2026 and 2030.

The company said the portfolio is geographically concentrated in lower-risk jurisdictions, with most assets located in Canada, Australia and South America, and diversified across both brine-based and hard-rock lithium production.

At the current spot price, Altius expects the acquired royalties to contribute between US$29 million and US$43.7 million in annual revenue by the end of the decade. Lithium carbonate equivalent prices fell to multi-year lows in 2025, holding below US$9,000 per metric ton for most of the year, even as demand continues to expand beyond electric vehicles.

Altius said global lithium demand is expected to exceed 1.5 million metric tons of lithium carbonate equivalent in 2025, with supply deficits potentially re-emerging as early as 2026 after years of oversupply.

Altius Chief Executive Brian Dalton said lithium has “emerged as a mainstream scale mined commodity,” and described the acquired portfolio as featuring “very long resource lives,” strong cost positioning and low jurisdictional risk.

A special shareholders’ meeting is scheduled to happen no later than March 10, 2026.

If approved, the deal is expected to close in the first quarter of 2026, after which Lithium Royalty shares will be delisted and the company will cease to be a reporting issuer in Canada.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

As the year closes, Republicans are looking to the past for another dance with a partisan exercise that tested the party’s unity and delivered President Donald Trump his crowning legislative achievement of the year.

Budget reconciliation is how congressional Republicans rammed through Trump’s ‘big, beautiful bill,’ earlier this year. But it’s a time-consuming, labor-intensive process that laid bare intra-party divisions and nearly exploded before liftoff.

Still, some Republicans want to take another stab at reconciliation, which allows a party in power to advance legislation with just a simple majority in the Senate as long as it adheres to strict, budgetary parameters.

‘We can do two more reconciliation bills without a single Democratic vote,’ Sen. John Kennedy, R-La., told Fox News Digital. ‘Doesn’t mean we wouldn’t welcome Democratic votes, but we can do them without a single Democratic vote.’

Turning once again to reconciliation would help Senate Republicans, in particular, address one of Trump’s desires to kill the 60-vote filibuster threshold in the upper chamber without changing the precedent that Democrats, for years, have threatened to do.

But they need a plan, first.

That would come from Senate Budget Committee Chair Lindsey Graham, R-S.C., the de facto maestro of the reconciliation process. His committee was responsible for drafting the budget resolution that unlocked the process in the upper chamber earlier this year, and he is reportedly eying drafting another resolution in the new year.

‘It would be political malpractice not to do another reconciliation,’ Graham told Semafor.

But many Republicans acknowledged just how difficult reconciliation is, especially after the latest exercise that dominated much of Congress’ attention for the first half of the year.

Senate Majority Leader John Thune, R-S.D., told Fox News Digital that ‘it’s always hard, but it’s an option, and one that we’re not ruling in or ruling out.’

‘I would say you have to have a reason to do it, you know,’ Thune said. ‘I mean, you don’t just do reconciliation for the heck of it. You got to have a, you know, a specific purpose. And so we’ll see. I mean, that purpose may, you know, may start getting some traction.’

Kennedy floated using reconciliation to tackle affordability issues, but some see the painstaking process as an avenue to grapple with another issue that has dominated Congress for several months: healthcare.

Lawmakers left Washington, D.C., without a fix to expiring Obamacare subsidies, effectively setting up a drastic hike in out-of-pocket healthcare costs for millions of Americans. There are bipartisan negotiations in the works to deal with the issue when lawmakers return, but Republicans have a gnawing appetite to drastically change the program.

Sen. Jim Banks, R-Ind., told Fox News Digital that Republicans ‘have to do something’ on healthcare.

‘Reconciliation is one pathway to do something, but it also limits what we can do,’ Banks said. ‘So we need bipartisan support to pass something that will help everybody.’

And Sen. Jim Justice, R-W.Va., who has been critical of Republicans’ inability to get a healthcare solution across the line, told Fox News Digital that reconciliation ‘may be an answer.’

‘The healthcare situation is really, it’s a big deal,’ Justice said. ‘It’s more than difficult, you know? And so we need to, we need to try to fix it. That’s for sure.’

This post appeared first on FOX NEWS